Jun. 11 at 8:19 PM
Stifel on
$ORIC said: We resume coverage of ORIC Pharmaceuticals with a Buy Rating and a
$14 target price.
$PFE $JNJ IPSEY DSNKY
Stifel added—ORIC's lead asset, rinzimetostat, is a PRC2 complex inhibitor being developed in combination with darolutamide in metastatic castration resistant prostate cancer (mCRPC) — a Ph3 clinical trial (Himalayas-1) is expected to initiate in June/July 2026 in mCRPC patients previously treated with abiraterone.
Logic for the combination is PRC2 inhibition blocks/reverts epigenetic reprogramming, resensitizing prostate cancer cells to androgen receptor pathway inhibitors (ARPIs) like darolutamide.
ORIC has cash runway out to 2H28, getting them through Himalayas-1 top-line data expected in early 2028.
